Alkermes plc., formerly Alkermes, Inc., is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. The Company develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. In September 2011, the Company started its corporate operations in Ireland. On September 16, 2011, the Company merged with Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan Corporation, plc (Elan).